EIF4E-IN-6
EIF4E-IN-6 (compound 4b) is a GMP analogs synthesized to targeteIF4Eand restrain its binding to cap mRNA.eIF4E-IN-6shows cell cytotoxicity against Caco-2, HepG-2, and MCF-7 cells, withIC50values of 31, 27, and 21 μM, respectively[1].
Product Specifications
UNSPSC
12352005
Target
Eukaryotic Initiation Factor (eIF)
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/eif4e-in-6.html
Solubility
10 mM in DMSO
Smiles
O=C1NC(NC(C2=CC=CC=C2)=O)=NC3=C1[N+](CC4=CC=CC=C4)=CN3C5OC(COP(NNC6=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C6)(O[Na])=O)C7C5OC(C)(C)O7.[Br-]
Molecular Formula
C33H32BrN9NaO12P
Molecular Weight
880.53
References & Citations
[1]Attia RT, et al. Newly Synthesized Anticancer Purine Derivatives Inhibiting p-EIF4E Using Surface-Modified Lipid Nanovesicles. ACS Omega. 2023;8 (41) :37864-37881. Published 2023 Oct 6.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC471129-100 1x 100 µL
MHC II (HLA-DP) (beta chain) (Bra-14), CF647 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 